PL2119441T3 - Zastosowanie antagonistów receptora angiotensyny II do podwyższania wrażliwości na insulinę - Google Patents
Zastosowanie antagonistów receptora angiotensyny II do podwyższania wrażliwości na insulinęInfo
- Publication number
- PL2119441T3 PL2119441T3 PL09160568T PL09160568T PL2119441T3 PL 2119441 T3 PL2119441 T3 PL 2119441T3 PL 09160568 T PL09160568 T PL 09160568T PL 09160568 T PL09160568 T PL 09160568T PL 2119441 T3 PL2119441 T3 PL 2119441T3
- Authority
- PL
- Poland
- Prior art keywords
- angiotensin
- ppargamma
- inhibitor
- telmisartan
- activity
- Prior art date
Links
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 3
- 206010022489 Insulin Resistance Diseases 0.000 title abstract 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 abstract 4
- 239000005537 C09CA07 - Telmisartan Substances 0.000 abstract 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
- 229960005187 telmisartan Drugs 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 abstract 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 abstract 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000001280 Prediabetic State Diseases 0.000 abstract 1
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- 229940100389 Sulfonylurea Drugs 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 229940083712 aldosterone antagonist Drugs 0.000 abstract 1
- 239000002170 aldosterone antagonist Substances 0.000 abstract 1
- 229960000528 amlodipine Drugs 0.000 abstract 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000003705 antithrombocytic agent Substances 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 abstract 1
- 229960003009 clopidogrel Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 abstract 1
- 229960002768 dipyridamole Drugs 0.000 abstract 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960001208 eplerenone Drugs 0.000 abstract 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 abstract 1
- 239000000833 heterodimer Substances 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960001597 nifedipine Drugs 0.000 abstract 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 abstract 1
- 230000000858 peroxisomal effect Effects 0.000 abstract 1
- 229960005095 pioglitazone Drugs 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 229960002354 repaglinide Drugs 0.000 abstract 1
- 229960004586 rosiglitazone Drugs 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
- 229960002256 spironolactone Drugs 0.000 abstract 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 abstract 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10335027A DE10335027A1 (de) | 2003-07-31 | 2003-07-31 | Verwendung von Angiotensin II Rezeptor Antagonisten |
| DE10346260A DE10346260A1 (de) | 2003-07-31 | 2003-10-06 | Verwendung von Angiotensin II Rezeptor Antagonisten |
| DE10356815A DE10356815A1 (de) | 2003-07-31 | 2003-12-05 | Verwendung von Angiotensin II Rezeptor Antagonisten |
| EP04763484A EP1651213B2 (de) | 2003-07-31 | 2004-07-24 | Verwendung von angiotensin ii rezeptor antagonisten, insbesondere von telmisartan, zur steigerung der insulinsensitivität |
| EP20090160568 EP2119441B1 (de) | 2003-07-31 | 2004-07-24 | Verwendung von Angiotensin II Rezeptor Antagonisten zur Steigerung der Insulinsensitivität |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2119441T3 true PL2119441T3 (pl) | 2015-10-30 |
Family
ID=34119379
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04763484T PL1651213T5 (pl) | 2003-07-31 | 2004-07-24 | Zastosowanie antagonistów receptora angiotensyny II, w szczególności telmisartanu, do zwiększenia wrażliwości na insulinę |
| PL09160568T PL2119441T3 (pl) | 2003-07-31 | 2004-07-24 | Zastosowanie antagonistów receptora angiotensyny II do podwyższania wrażliwości na insulinę |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04763484T PL1651213T5 (pl) | 2003-07-31 | 2004-07-24 | Zastosowanie antagonistów receptora angiotensyny II, w szczególności telmisartanu, do zwiększenia wrażliwości na insulinę |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20050070594A1 (pl) |
| EP (3) | EP1651213B2 (pl) |
| JP (1) | JP4833840B2 (pl) |
| KR (1) | KR20060054404A (pl) |
| CN (3) | CN1829511B (pl) |
| AT (1) | ATE443519T1 (pl) |
| AU (1) | AU2004260606B2 (pl) |
| BR (1) | BRPI0413165A (pl) |
| CA (1) | CA2534006C (pl) |
| CY (1) | CY1109560T1 (pl) |
| DE (4) | DE10335027A1 (pl) |
| DK (2) | DK2119441T3 (pl) |
| EA (2) | EA017640B1 (pl) |
| EC (1) | ECSP066303A (pl) |
| ES (2) | ES2543722T3 (pl) |
| HU (1) | HUE027274T2 (pl) |
| IL (1) | IL172693A (pl) |
| ME (1) | MEP51108A (pl) |
| MX (1) | MXPA06001322A (pl) |
| NO (1) | NO335444B1 (pl) |
| NZ (1) | NZ544877A (pl) |
| PL (2) | PL1651213T5 (pl) |
| PT (1) | PT1651213E (pl) |
| RS (1) | RS50793B (pl) |
| SI (1) | SI1651213T2 (pl) |
| UA (1) | UA83854C2 (pl) |
| WO (1) | WO2005011680A1 (pl) |
| ZA (1) | ZA200509835B (pl) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK286975B6 (sk) * | 2001-02-24 | 2009-08-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
| EP1814527B2 (en) * | 2004-11-05 | 2020-11-18 | Boehringer Ingelheim International GmbH | Bilayer tablet comprising telmisartan and amlodipine |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| CN1298389C (zh) * | 2005-01-18 | 2007-02-07 | 广东省人民医院 | 一种含替米沙坦和钙离子拮抗剂的复方降压制剂及其应用 |
| WO2006136916A2 (en) * | 2005-06-20 | 2006-12-28 | Glenmark Pharmaceuticals Limited | Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2007050485A2 (en) * | 2005-10-25 | 2007-05-03 | Merck & Co., Inc. | Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
| RU2308947C1 (ru) * | 2006-02-26 | 2007-10-27 | Новосибирский институт органической химии им. Н.Н. Ворожцова СО РАН (НИОХ СО РАН) | Лекарственное средство с гиполипидемическим эффектом "симваглизин" |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) * | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| WO2008021666A2 (en) * | 2006-08-18 | 2008-02-21 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| CN101260103A (zh) * | 2007-03-09 | 2008-09-10 | 上海艾力斯医药科技有限公司 | 一类具有部分PPARγ激动剂活性的化合物及其应用 |
| WO2008125388A1 (en) * | 2007-04-17 | 2008-10-23 | Ratiopharm Gmbh | Pharmaceutical compositions comprising irbesartan |
| RU2344818C1 (ru) * | 2007-07-09 | 2009-01-27 | Илья Николаевич Медведев | СПОСОБ НОРМАЛИЗАЦИИ УРОВНЯ α2-АНТИПЛАЗМИНА ПРИ МЕТАБОЛИЧЕСКОМ СИНДРОМЕ |
| RU2339375C1 (ru) * | 2007-07-09 | 2008-11-27 | Илья Николаевич Медведев | Способ коррекции вазопатии при метаболическом синдроме |
| RU2345765C1 (ru) * | 2007-07-09 | 2009-02-10 | Илья Николаевич Медведев | Способ коррекции гиперфибриногенемии при метаболическом синдроме |
| RU2345767C1 (ru) * | 2007-07-09 | 2009-02-10 | Илья Николаевич Медведев | Способ быстрой нормализации эндотелиоцитемии при метаболическом синдроме |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| RU2387449C1 (ru) * | 2008-08-05 | 2010-04-27 | Государственное образовательное учреждение дополнительного профессионального образования Санкт-Петербургская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию | Способ лечения гипертензивных внутримозговых кровоизлияний |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| BRPI0919288A2 (pt) | 2008-09-10 | 2015-12-15 | Boehring Ingelheim Internat Gmbh | teriapia de combinação para tratamento de diabetes e condições relacionadas. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| CN101869567A (zh) * | 2009-04-24 | 2010-10-27 | 北京奥萨医药研究中心有限公司 | 含有双胍类降糖药物和沙坦类降压药物的药物组合物及其用途 |
| DK2432452T3 (en) | 2009-05-20 | 2016-10-10 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutically telmisartan drink solution |
| KR101069166B1 (ko) * | 2009-06-02 | 2011-09-30 | 한국화학연구원 | 이미다조 페닐테트라졸 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 골다공증 또는 비만의 예방 또는 치료용 약학적 조성물 |
| PH12012501037A1 (en) | 2009-11-27 | 2013-01-14 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| RU2423125C1 (ru) * | 2010-02-15 | 2011-07-10 | Илья Николаевич Медведев | Способ нивелирования дисфункций сосудистой стенки у больных артериальной гипертонией iii степени при метаболическом синдроме, перенесших тромбоз сосудов глаза |
| RU2423126C1 (ru) * | 2010-02-15 | 2011-07-10 | Илья Николаевич Медведев | Способ коррекции функций стенки сосудов у больных артериальной гипертонией i-ii степени при метаболическом синдроме, перенесших тромбоз сосудов глаза |
| RU2422141C1 (ru) * | 2010-02-15 | 2011-06-27 | Илья Николаевич Медведев | Способ нормализации функциональной активности стенки сосудов у больных артериальной гипертонией i-ii степени при метаболическом синдроме, перенесших тромбоз сосудов глаза |
| CA2797310C (en) | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| PT2640371T (pt) * | 2010-11-15 | 2020-04-17 | Boehringer Ingelheim Int | Terapia antidiabética vasoprotetora e cardioprotetora |
| ES2713566T3 (es) | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| RU2699508C1 (ru) * | 2018-07-25 | 2019-09-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ лечения больных метаболическим синдромом |
| CN114073697B (zh) * | 2021-01-19 | 2023-01-24 | 复旦大学附属肿瘤医院 | Bcat2抑制剂在制备预防和/或治疗bcat2介导的相关代谢疾病药物中的用途 |
| CN114786683B (zh) | 2021-04-09 | 2024-01-12 | 北京大学 | 一种siRNA、药物组合物以及使用其治疗糖尿病的方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4265847A (en) * | 1978-03-30 | 1981-05-05 | Kirby Pharmaceuticals Ltd | Tabletting process |
| JPS5671074A (en) | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
| DK161312C (da) * | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
| CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| CA1338238C (en) | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| US4880804A (en) | 1988-01-07 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking benzimidazoles |
| US5015651A (en) | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
| IE70593B1 (en) | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
| IL97219A (en) | 1990-02-19 | 1995-12-08 | Ciba Geigy Ag | Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them |
| PT97078B (pt) | 1990-03-20 | 1997-07-31 | Sanofi Sa | Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem |
| US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| IE912956A1 (en) | 1990-09-10 | 1992-03-11 | Abbott Lab | Angiotensin ii receptor antagonists |
| SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| US5196537A (en) | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
| GB9110636D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
| US6162802A (en) * | 1992-03-10 | 2000-12-19 | Papa; Joseph | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor |
| EP0636027B1 (en) | 1992-04-13 | 1999-07-07 | Zeneca Limited | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
| US5824696A (en) | 1993-09-01 | 1998-10-20 | Smithkline Beecham Corporation | Medicaments |
| WO1995026188A1 (en) | 1994-03-29 | 1995-10-05 | Merck & Co., Inc. | Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles |
| US5496831A (en) * | 1994-05-13 | 1996-03-05 | The General Hospital Corporation | Inhibition of insulin-induced adiposis |
| ES2175098T3 (es) * | 1995-06-07 | 2002-11-16 | Searle & Co | Terapia de combinacion de espironolactona y antagonista de angiotensina hi para el tratamiento del fallo cardiaco congestivo. |
| US6087386A (en) * | 1996-06-24 | 2000-07-11 | Merck & Co., Inc. | Composition of enalapril and losartan |
| US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| CA2332608C (en) * | 1998-06-17 | 2010-03-23 | Bristol-Myers Squibb Company | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
| DK1096932T3 (da) * | 1998-07-10 | 2007-10-15 | Novartis Pharma Ag | Antihypertensiv kombination af valsartan og calciumkanalblokker |
| WO2000027397A1 (en) * | 1998-11-06 | 2000-05-18 | Glaxo Group Limited | Antihypertensive medicaments containing lacidipine and telmisartan |
| UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| CZ301913B6 (cs) * | 1999-04-28 | 2010-07-28 | Takeda Pharmaceutical Company Limited | Farmaceutický prípravek pro predcházení, lécení nebo inhibování vývoje jednoduché retinopatie nebo predproliferacní retinopatie |
| EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| SK14642002A3 (sk) * | 2000-04-12 | 2003-05-02 | Novartis Ag | Kombinované farmaceutické prostriedky obsahujúce antagonistu AT1-receptora a/alebo inhibítor HMG-CoA reduktázy a/alebo ACE inhibítor |
| US6784207B2 (en) * | 2000-08-04 | 2004-08-31 | Roche Vitamins Inc. | Phytanic acid derivative compositions |
| AU2002226365A1 (en) * | 2000-12-01 | 2002-06-11 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
| US20030078190A1 (en) * | 2001-05-25 | 2003-04-24 | Weinberg Marc S. | Methods for tissue protection using highly effective inhibition of the renin-angiotensin system |
| JP2003113120A (ja) * | 2001-08-03 | 2003-04-18 | Takeda Chem Ind Ltd | 徐放性医薬 |
| US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
| AUPS236902A0 (en) * | 2002-05-16 | 2002-06-13 | Northern Sydney Area Health Service | Composition and method for treating hypertension |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| US8980870B2 (en) * | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
| EP1587584B1 (de) * | 2003-01-16 | 2007-05-23 | Boehringer Ingelheim International GmbH | Pharmazeutische kombination zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten |
| DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
| DE10306179A1 (de) * | 2003-02-13 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
| US9029363B2 (en) * | 2003-04-30 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Telmisartan sodium salt pharmaceutical formulation |
-
2003
- 2003-07-31 DE DE10335027A patent/DE10335027A1/de not_active Withdrawn
- 2003-10-06 DE DE10346260A patent/DE10346260A1/de not_active Withdrawn
- 2003-12-05 DE DE10356815A patent/DE10356815A1/de not_active Withdrawn
-
2004
- 2004-07-24 EA EA200900929A patent/EA017640B1/ru not_active IP Right Cessation
- 2004-07-24 DK DK09160568.3T patent/DK2119441T3/en active
- 2004-07-24 PT PT04763484T patent/PT1651213E/pt unknown
- 2004-07-24 BR BRPI0413165-7A patent/BRPI0413165A/pt active Search and Examination
- 2004-07-24 IL IL172693A patent/IL172693A/en not_active IP Right Cessation
- 2004-07-24 EP EP04763484A patent/EP1651213B2/de not_active Revoked
- 2004-07-24 UA UAA200601929A patent/UA83854C2/uk unknown
- 2004-07-24 MX MXPA06001322A patent/MXPA06001322A/es active IP Right Grant
- 2004-07-24 CN CN2004800220966A patent/CN1829511B/zh not_active Expired - Lifetime
- 2004-07-24 EP EP10177920.5A patent/EP2263670B1/de not_active Revoked
- 2004-07-24 PL PL04763484T patent/PL1651213T5/pl unknown
- 2004-07-24 DK DK04763484.5T patent/DK1651213T4/da active
- 2004-07-24 PL PL09160568T patent/PL2119441T3/pl unknown
- 2004-07-24 WO PCT/EP2004/008326 patent/WO2005011680A1/de not_active Ceased
- 2004-07-24 HU HUE09160568A patent/HUE027274T2/en unknown
- 2004-07-24 AU AU2004260606A patent/AU2004260606B2/en not_active Revoked
- 2004-07-24 SI SI200431301T patent/SI1651213T2/sl unknown
- 2004-07-24 AT AT04763484T patent/ATE443519T1/de active
- 2004-07-24 CA CA2534006A patent/CA2534006C/en not_active Expired - Fee Related
- 2004-07-24 RS YUP-2006/0066A patent/RS50793B/sr unknown
- 2004-07-24 NZ NZ544877A patent/NZ544877A/en not_active IP Right Cessation
- 2004-07-24 ES ES09160568.3T patent/ES2543722T3/es not_active Expired - Lifetime
- 2004-07-24 CN CN2010102582634A patent/CN101926997A/zh active Pending
- 2004-07-24 JP JP2006521497A patent/JP4833840B2/ja not_active Expired - Fee Related
- 2004-07-24 CN CN2011100821828A patent/CN102139110A/zh active Pending
- 2004-07-24 ME MEP-511/08A patent/MEP51108A/xx unknown
- 2004-07-24 DE DE502004010117T patent/DE502004010117D1/de not_active Expired - Lifetime
- 2004-07-24 EA EA200600161A patent/EA012600B1/ru not_active IP Right Cessation
- 2004-07-24 EP EP20090160568 patent/EP2119441B1/de not_active Revoked
- 2004-07-24 KR KR1020067002186A patent/KR20060054404A/ko not_active Ceased
- 2004-07-24 ES ES04763484T patent/ES2334136T5/es not_active Expired - Lifetime
- 2004-07-27 US US10/899,784 patent/US20050070594A1/en not_active Abandoned
-
2005
- 2005-12-05 ZA ZA200509835A patent/ZA200509835B/xx unknown
-
2006
- 2006-01-23 EC EC2006006303A patent/ECSP066303A/es unknown
- 2006-02-27 NO NO20060938A patent/NO335444B1/no not_active IP Right Cessation
-
2009
- 2009-12-04 CY CY20091101278T patent/CY1109560T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2119441T3 (pl) | Zastosowanie antagonistów receptora angiotensyny II do podwyższania wrażliwości na insulinę | |
| Lacourcière et al. | Sustained antihypertensive activity of telmisartan compared with valsartan | |
| Wang et al. | Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients | |
| PT1925303E (pt) | Utilização de antagonistas do receptor tipo 1 da angiotensina ii para a prevenção de diabetes | |
| SE0202803D0 (sv) | Implantable medical device | |
| Eguchi et al. | Add‐on use of eplerenone is effective for lowering home and ambulatory blood pressure in drug‐resistant hypertension | |
| Chrysant et al. | Efficacy and safety of long‐term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension | |
| Basra et al. | Application of the dermatology life quality index in clinical trials of biologics for psoriasis | |
| WO2004075856A3 (en) | Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases | |
| Weir et al. | The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed‐dose combination in hypertensive patients with and without high cardiovascular risk | |
| EA200401137A1 (ru) | Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора | |
| Black et al. | Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: the ACQUIRE randomized double‐blind study | |
| Perez et al. | The impact of azilsartan medoxomil treatment (capsule formulation) at doses ranging from 10 to 80 mg: significant, rapid reductions in clinic diastolic and systolic blood pressure | |
| Bălan et al. | Comparing different treatment schedules of Zomen (zofenopril) | |
| Ruilope | Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension | |
| White et al. | Utility of semiautomatic clinic and 24-h ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril–Hydrochlorothiazide Hypertension Trial | |
| Pontremoli et al. | Cardiovascular and renal risk assessment as a guide for treatment in primary hypertension | |
| Ibuki et al. | The fixed-dose combination of losartan/hydrochlorothiazide elicits potent blood pressure lowering during nighttime in obese hypertensive patients | |
| CO5560583A2 (es) | Composiciones medicinales que comprenden antagonistas del receptor de angiotensina ii | |
| WO2003085127A3 (en) | Method for identification of insulin receptor kinase activators |